A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)
Phase of Trial: Phase II/III
Latest Information Update: 08 Sep 2017
At a glance
- Drugs Depatuxizumab mafodotin (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms Intellance1
- Sponsors AbbVie
- 12 Jan 2017 Planned End Date changed from 1 Mar 2020 to 1 Apr 2020.
- 08 Oct 2015 Status changed from planning to recruiting, as reported by ClinicalTrials.gov.
- 14 Nov 2014 Based on the results of a phase I study, AbbVie will advance ABT 414 into this randomised phase II trial in patients with glioblastoma multiforme, according to a media release.